Why Insys Therapeutics (INSY) Stock Is Plunging Today

NEW YORK (TheStreet) -- Insys Therapeutics  (INSY) continued to plunge Wednesday after the company announced first-quarter results that came up short of analysts' expectations.

Insys reported earnings of 23 cents a share, which was less than the consensus estimate of 28 cents a share. Revenue totaled $41.6 million, which was short of the consensus estimate of $45.63 million.

The stock was down 14.65% to $23.30 at 2:21 p.m.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

INSY Chart

INSY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers